Bristol-Myers Squibb Company
BMYHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, Bristol-Myers Squibb Company (BMY) is listed under Drug Manufacturers - General. At a $124.04B market cap, Bristol-Myers Squibb Company ranks as a large-cap company within healthcare. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Market Cap
$124.04B
Beta
0.23
P/E (TTM)
16.97
P/E (Fwd)
9.80
EPS (TTM)
$3.58
EPS (Fwd)
$6.20
ROE
38.7%
ROA
10.7%
Cash
$10.49B
Total Debt
$46.43B
Free CF
$9.85B
52W Change
28.2%
Annual Financials
Cash vs Debt
The company holds $10.49B in cash, though total debt stands at $46.43B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $9.85B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 38.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 10.7% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $46.16B (2022) to $48.20B (2025).
With a beta below 0.7, Bristol-Myers Squibb Company typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Bristol-Myers Squibb Company's trajectory.